VCYT
$41.25
$-1.30 (-3.05%)-3.05%
ClosedLoading chart...
IndexN/A
Market Cap3.29B
Enterprise Value2.99B
Income$0.01B
Sales$0.11B
EmployeesN/A
P/E20.63
P/S6.40
P/B2.53
P/C26.13
EV/EBITDA33.31
EV/SalesN/A
EPS (ttm)2.00
EarningsN/A
Gross Margin69.62%
Oper. Margin14.34%
Profit Margin12.83%
Volume1.67M
Shs Outstand0.08B
Change-3.17%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $445.76M | $361.05M | $296.54M | $219.51M | $117.48M | $120.37M | $92.01M | $71.95M |
| Cost of Revenue | $147.62M | $112.90M | $101.58M | $74.40M | $41.45M | $36.52M | $33.08M | $28.20M |
| Gross Profit | $298.14M | $248.15M | $194.95M | $145.11M | $76.03M | $83.84M | $58.93M | $43.76M |
| Gross Margin | 66.88% | 68.73% | 65.74% | 66.11% | 64.71% | 69.66% | 64.05% | 60.81% |
| Operating Expenses | $282.00M | $333.94M | $236.03M | $227.02M | $111.42M | $98.97M | $81.16M | $70.30M |
| Operating Income | $16.14M | $-85.80M | $-41.08M | $-81.90M | $-35.39M | $-15.13M | $-22.23M | $-26.54M |
| Operating Margin | 3.62% | -23.76% | -13.85% | -37.31% | -30.12% | -12.57% | -24.16% | -36.88% |
| Net Income | $24.14M | $-74.40M | $-36.56M | $-75.56M | $-34.91M | $-12.60M | $-23.00M | $-31.00M |
| Net Margin | 5.41% | -20.61% | -12.33% | -34.42% | -29.71% | -10.47% | -25.00% | -43.09% |
| EPS (Basic) | $0.32 | $-1.02 | $-0.51 | $-1.11 | $-0.66 | $-0.27 | $-0.62 | $-0.91 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $1.30B | $1.11B | $1.16B | $1.19B | $457.16M | $275.21M | $120.64M | $78.67M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $124.07M | $70.80M | $81.22M | $91.31M | $35.93M | $35.76M | $40.88M | $41.44M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.18B | $1.04B | $1.08B | $1.10B | $421.23M | $239.46M | $79.75M | $37.23M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.18B | $1.04B | $1.08B | $1.10B | $421.23M | $239.46M | $79.75M | $37.23M |
| Total Liabilities & Stockholders Equity | $1.30B | $1.11B | $1.16B | $1.19B | $457.16M | $275.21M | $120.64M | $78.67M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $24.14M | $-74.40M | $-36.56M | $-75.56M | $-34.91M | $-12.60M | $-23.00M | $-31.00M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $75.10M | $44.22M | $7.54M | $-31.62M | $-9.71M | $-3.23M | $-13.52M | $-23.91M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention FocusBenzinga Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand WorldwideGlobeNewswire Inc. Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term PositiveBenzinga Should You Continue to Retain PODD Stock in Your Portfolio Now?Benzinga Globus Medical (GMED) Global Sales, Innovation Aid Growth - Zacks Investment ResearchZacks Investment Research Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) By GuruFocus - Investing.com CanadaInvesting.com 3 Medical Instruments Picks to Navigate Industry ChallengesZacks Investment Research Zacks.com featured highlights Veracyte, Steelcase and Applied IndustrialZacks Investment Research
Show 12 more stories
3 Top-Ranked Efficient Stocks to Increase Your Portfolio ReturnsZacks Investment Research Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?Zacks Investment Research How to Find Strong Buy Medical Stocks Using the Zacks RankZacks Investment Research Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a BetZacks Investment Research Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research Zacks.com featured highlights include Veracyte, Signet Jewelers, UMB Financial and NVIDIAZacks Investment Research Looking for Medical Stocks? The Zacks Rank Can Help You Find WinnersZacks Investment Research 4 Must-Buy Efficient Stocks to Enrich Your PortfolioZacks Investment Research Veracyte's (VCYT) New Findings to Advance Thyroid Cancer CareZacks Investment Research Buy 5 Medical Instruments Stocks to Enhance Your PortfolioZacks Investment Research Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?Zacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Discover more
You may be interested in